2025 EPS consensus $5.18. Raises 2025 revenue view to $1.30B-$1.375B from $1.275B-$1.355B, consensus $1.32B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme reports Q3 non-GAAP EPS $1.72, consensus $1.61
- Is HALO a Buy, Before Earnings?
- Halozyme price target raised to $65 from $63 at JPMorgan
- Buy Rating for Halozyme: Strong Growth Prospects Backed by Successful MajesTEC-3 Trial and Robust Financial Valuation
- Halozyme price target lowered to $79 from $80 at Morgan Stanley